Fellström BC, et al. N Engl J Med 2009;360:1455-7

Slides:



Advertisements
Similar presentations
Coronary heart disease (CHD) event rates in secondary prevention and acute coronary syndrome trials A. Kumar, C.P. Cannon. Arch Med Sci 2007;3:S115-S125.
Advertisements

Weng TC, et al. J Clin Pharm Ther 2010;35:
Slide Source: Lipid and Lipoprotein Parameters at Baseline and Drug Treatment: METEOR Trial Baseline, Mean (SD) Time-Weighted Average.
* Plus–minus values are means ±SD. † Race was determined by the investigator. ‡ The body-mass index is the weight in kilograms divided by the square of.
Glynn RJ, et al. N Engl J Med 2009 Mar 29 [Epub ahead of print]
© 2003, Wellsource Inc. Effect of Ketogenic Diet on Lipid Levels (shown is LDL-C) In this group of 141 children followed for 6 months, a ketogenic diet.
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy Kahn SE, et al. (ADOPT Study Group) N Engl J Med 2006;355: Steven E. Kahn,
The ILLUMINATE Study: Enrollment and Outcomes Philip Barter, et al. N Engl J Med 2007;357:
Ridker PM, et al. Lancet 2009;373: Baseline clinical characteristics of the study population in the placebo and rosuvastatin groups according.
Flow of Patients Through the Trial Nissen SE, et al. JAMA 2008;299:
Trial profile Prakash Deedwania, et al. Lancet 2006; 368:
Trial profile The FIELD study investigators, Lancet Published online November 14, 2005.
Rosuvastatin 10 mg n=2514 Placebo n= to 4 weeks Randomization 6weeks3 monthly Closing date 20 May 2007 Eligibility Optimal HF treatment instituted.
Enrollment and Outcomes Duckworth W, et al. N Engl J Med 2009;360:
Patients’ Assignments,Values at Screening, and Baseline Efficacy and Safety Values - PartI JP Després, N Engl J Med 2005; 353:
Date of download: 6/22/2016 Copyright © 2016 American Medical Association. All rights reserved. From: Total Cholesterol/HDL Cholesterol Ratio vs LDL Cholesterol/HDL.
The SPRINT Research Group
Arch Intern Med. 2004;164(13): doi: /archinte Figure Legend:
Flow of Individuals Through the Vitamin E and Vitamin C Components of the Physicians’ Health Study II Howard D. Sesso et al. JAMA 2008;300:
Trial profile SAS denotes the Simvastatin in Aortic Stenosis Study
Baseline Characteristics of the Patients Part I
Fig. 1. Serum total cholesterol (A), LDL cholesterol (B), triglyceride (C) and HDL cholesterol level (D) according to HBsAg status in age group. Total.
Copyright © 2002 American Medical Association. All rights reserved.
Copyright © 2009 American Medical Association. All rights reserved.
Baseline Characteristics of Women and Men in Whom Coronary Heart Disease Developed during Follow-up and Matched Controls - A Jennifer K. Pai et al. N.
Fig. 1. Mean plasma lipid and lipoprotein levels as a function of the common genetic variants in LCAT, g.-293G>A, S208T, and L369L in the CCHS and S208T.
Copyright © 2012 American Medical Association. All rights reserved.
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
TNT: Baseline and final LDL cholesterol levels
Effects of High Density Lipoprotein Raising Therapies on Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus, with or without Renal Impairment:
Effect of evolocumab on lipoprotein particles
TNT Study: Baseline Characteristics of the Patients
Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles  Jan.
I. Introduction American Journal of Kidney Diseases
Lipid and lipoprotein reference values from 133,450 Dutch Lifelines participants: Age- and gender-specific baseline lipid values and percentiles  Jan.
Q.A. Truong et al. Circ Cardiovasc Qual Outcomes 2011;4:
Baseline Characteristics of the Study Cohort*
Plus–minus values are means ±SE
Daan Kromhout, et al. NEJM epub August 29, 2010
Enrollment and Outcomes
Baseline Characteristics, Values at 24-Month Follow-up, and Changes from Baseline* - Part I John J.P. Kastelein, et al. N Engl J Med 2007;356: online.
Inclusion Criteria for Patients with Multiple Atherothrombotic Risk Factors and for Those with Established Cardiovascular Disease Deepak L.Bhatt, et al,
Flow of Patients Through the Trial
Characteristics of the Patients at Baseline*
Baseline Characteristics According to Sex
Flow of Patients Through Trial
Flow diagram for exclusions of trials identified RCT indicates randomized controlled trial Hulten E, et al. Arch Intern Med 2006;166:
Study Participant Flow
Baseline Characteristics of the Patients and Use of Concomitant Medications – Part I Kaare Harald Bønaa, et al. N Engl J Med 2006;354:
Baseline Characteristics of the Study Participants
Baseline Characteristics, Blood Pressures, and Laboratory Values
Baseline Characteristics of the Subjects*
Patient Disposition James A. de Lemos et al. JAMA 2004; 292:
Age-Standardized Rates of Death from Any Cause According to the Estimated GFR among 1,120,295 Ambulatory Adults Alan S.Go et al. N Engl J Med 2004; 351:
Study Flow Diagram Thompson A, et al. JAMA 2008;299:
Disposition of Patients in the Atherogenic Dyslipidemia Study
(A) Low-density lipoprotein-cholesterol (LDL-C) values at baseline and after treatment with anagliptin in 20 participants at 12 and 24 weeks. (A) Low-density.
Entry, Randomization, and Follow-up of Patients in the Hypertension in the Very Elderly Trial Of the 461 patients who did not meet the protocol criteria,
Baseline Characteristics of Elderly Participants in the Cardiovascular Health Study,According to Quintiles of Cystatin C Michael G.Shlipak et al N Engl.
Baseline Characteristics of the Patients – Part I
RECORD Study: Enrollment and Outcomes
The ACCORD Study Group. NEJM 2010; Epub March 14
Enrollment and Outcomes
Titration activities from baseline up to 6 and 12 months follow-up in nurse-coordinated care (NCC) versus usual care patients. X-as: patients (percentage),
The ACCORD Study Group. NEJM 2010; Epub March 14
SPIRE Program: Studies of PCSK9 Inhibition and the Reduction of Vascular Events Unanticipated attenuation of LDL-c lowering response to humanized PCSK9.
Flow of study participants
Individual lipid measures for high-carbohydrate (n=10) and low-carbohydrate (n=10) ultra-endurance athletes. Individual lipid measures for high-carbohydrate.
International Journal of Cardiology
The cumulative incidence curve demonstrated that patients with a sub-optimal LDL-C response to statin therapy were associated with a higher risk of CVD.
Presentation transcript:

Fellström BC, et al. N Engl J Med 2009;360:1455-7

Baseline Characteristics of the Patients* - Part I Fellström BC, et al. N Engl J Med 2009;360:1455-7

Baseline Characteristics of the Patients* - Part II Fellström BC, et al. N Engl J Med 2009;360:1455-7

Changes in Levels of Lipids and C-Reactive Protein, According to Study Group Panel A shows low-density lipoprotein (LDL) cholesterol levels, Panel B triglyceride levels, Panel C high-density lipoprotein (HDL) cholesterol levels, and Panel D high-sensitivity C-reactive protein levels. P values are for between-group comparisons of the percent change from baseline to 3 months in lipid levels, calculated with the use of analysis of variance with baseline values as covariates, and in C-reactive protein levels, calculated with the use of the two-sample sign test. I bars denote 95% confidence intervals. To convert values for LDL, HDL, and total cholesterol to millimoles per liter, multiply by 0.02586. To convert values for triglycerides to millimoles per liter, multiply by 0.01129. Fellström BC, et al. N Engl J Med 2009;360:1455-7

Kaplan–Meier Curves for the Primary End Point in the Two Study Groups The primary end point was the first major cardiovascular event. Fellström BC, et al. N Engl J Med 2009;360:1455-7

End Points According to Study Group* Fellström BC, et al. N Engl J Med 2009;360:1455-7

Hazard Ratio for the Primary End Point in Predefined Subgroups In the age category, the two subgroups shown are patients with a baseline age below the median value and those with a baseline age above the median. For categories with three subgroups, patients are divided according to their baseline values. Values for low-density lipoprotein (LDL) cholesterol were calculated with the use of Friedewald’s formula; to convert the values to millimoles per liter, multiply by 0.02586. Fellström BC, et al. N Engl J Med 2009;360:1455-7

Monitored Adverse Events and Measured Laboratory Values in the Safety-Analysis Population* Fellström BC, et al. N Engl J Med 2009;360:1455-7